<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23429">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976013</url>
  </required_header>
  <id_info>
    <org_study_id>MUV-Coagu</org_study_id>
    <nct_id>NCT01976013</nct_id>
  </id_info>
  <brief_title>Prediction of Major Bleeding in ELBW-infants (&lt;1000g) by Sequential Coagulation Monitoring</brief_title>
  <official_title>Prediction of Major Bleeding in Extremely Low Birth Weight Infants (&lt;1000g) by Sequential Coagulation Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to now, only data about early and single coagulation screening exist in extreme low birth
      weight infants (ELBW) infants. In neonatal practice, coagulation abnormality in preterm
      babies is primarily investigated by measuring prothrombin time (PT). In fact, FVII activity,
      which is an important determinant of PT, is strongly associated with bleeding risk. Thus, a
      method to measure PT with small volume samples (10μL) provides the possibility for serial
      monitoring even in ELBW infants (CoaguChek®XS, Roche Diagnostics, Vienna, Austria)).
      Substitution of fesh frozen plasma seemed beneficial in ELBW infants and first trials with
      rFVII revealed promising results in this patient population. Thus, coagulation monitoring
      might lead to early and adequate therapy and therefore to a better outcome. The
      investigators hypothesize that ELBW infants (&lt;1000g birth weight) with primary severe
      prolongation of prothrombin time or development of severe prothrombin prolongation during
      sequential monitoring may have more frequent and more severe bleeding incidents
      (Intraventricular haemorrhage and pulmonary haemorrhage). The investigators aim to explore
      whether monitoring of PT can predict bleeding events in ELBW children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>major bleeding</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>pulmonary bleeding, intraventricular hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Intraventricular Haemorrhage</condition>
  <condition>Pulmonary Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Coaguchek</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>infants will receive sequential coagulation checks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coaguchek</intervention_name>
    <description>The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.</description>
    <arm_group_label>Coaguchek</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants with a birth weight &lt;1000g

          -  signed informed consent

        Exclusion Criteria:

          -  Congenital heart disease

          -  major congenital birth defects
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadja Haiden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadja Haiden, MD</last_name>
    <phone>+431404003232</phone>
    <email>nadja.haiden@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margarita Thanhaeuser, MD</last_name>
    <phone>+431404003232</phone>
    <email>margarita.thanhaeuser@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja Haiden, MD</last_name>
      <phone>+431404003232</phone>
      <email>nadja.haiden@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Nadja Haiden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 10, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Nadja Haiden,MD</investigator_full_name>
    <investigator_title>Assoc.Prof.MD</investigator_title>
  </responsible_party>
  <keyword>PT</keyword>
  <keyword>INR</keyword>
  <keyword>intraventricular haemorrhage</keyword>
  <keyword>pulmonary haemorrhage</keyword>
  <keyword>ELBW infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hemoptysis</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
